Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.280
-0.050 (-2.15%)
May 15, 2026, 4:00 PM EDT - Market closed
Lipocine Employees
Lipocine had 14 employees as of December 31, 2025. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
$143,015
Profits / Employee
-$816,752
Market Cap
18.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% |
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Sep 30, 2022 | 17 | 4 | 30.77% |
| Jun 30, 2022 | 15 | 2 | 15.38% |
| Mar 31, 2022 | 13 | 0 | - |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Sep 30, 2021 | 13 | 2 | 18.18% |
| Jun 30, 2021 | 13 | - | - |
| Mar 31, 2021 | 13 | 1 | 8.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Passage Bio | 24 |
| Curis | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Holdings | 22 |
| SeaStar Medical Holding | 17 |
| NewcelX | 15 |
| Cocrystal Pharma | 10 |
LPCN News
- 8 days ago - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 - PRNewsWire
- 4 weeks ago - Lipocine price target lowered to $6 from $11 at Alliance Global - TheFly
- 5 weeks ago - Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 5 weeks ago - Lipocine downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 6 weeks ago - Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial - TheFly
- 6 weeks ago - Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - PRNewsWire
- 2 months ago - Lipocine price target raised to $11 from $6.75 at Alliance Global - TheFly
- 2 months ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PRNewsWire